Open AccessImpact of the Psychiatric Comorbidities in Chronic Obstructive Pulmonary Disease
Author(s) -
Lucreţia Anghel,
Bogdan Ioan Ștefănescu,
Diana Pătraș,
Liliana Baroiu,
Ioana Anca Ștefanopol,
Anamaria Ciubară
Publication year - 2022
Publication title -
broad research in artificial intelligence neuroscience
Language(s) - English
Resource type - Journals
eISSN - 2067-3957
pISSN - 2068-0473
DOI - 10.18662/brain/13.1/277
Subject(s) - copd , medicine , anxiety , depression (economics) , quality of life (healthcare) , clinical trial , disease , comorbidity , psychiatry , intensive care medicine , physical therapy , nursing , economics , macroeconomics
Chronic obstructive pulmonary disease (COPD) is one of the main causes of death with a significant impact on the quality of life and mental health of the patients as well as on the health system. The social costs of COPD are significant, because this pathology has a negative impact on patients's professional performance and daily activity. The major risk factors for COPD are age and smoking. Extrapulmonary comorbidities are frequently associated with COPD and may have an influence on the symptoms severity, and the frequency of the exacerbations, hospitalizations and mortality. Psychiatric disorders, especially anxiety and depression, have been observed in clinical trials with an increased prevalence of COPD. The relationship between anxiety, depression and COPD is complex. Psychiatric pathology is involved in influencing the pathophysiology of COPD with a proven impact on the patient's prognosis. COPD sleep disorders can aggravate pre-existing psychiatric pathology, the relationship between the two pathologies being bidirectional. The aim of this paper is to review the latest clinical trials on the existing evidence of psychiatric comorbidities impact on the evolution and prognosis of COPD and the therapeutic alternatives for their improvement. The conclusion of the present study is that anxiety and depression should be periodically assessed by a multidisciplinary team in order to provide a complete management (pharmacological, pulmonary rehabilitation and cognitive-behavioral therapy), improving the patient's quality of life and prognosis.